Cargando…
Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy
Introduction: Biotinidase deficiency (BD) is an autosomal recessive disease causing a defect in the biotin-releasing enzyme. Newborn screening (NBS) allows early diagnosis and treatment, ensuring excellent prognosis. The aim of this study was to describe our experience in the diagnosis, treatment, a...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200396/ https://www.ncbi.nlm.nih.gov/pubmed/34136440 http://dx.doi.org/10.3389/fped.2021.661416 |
_version_ | 1783707592831270912 |
---|---|
author | Maguolo, Alice Rodella, Giulia Dianin, Alice Monge, Irene Messina, Martina Rigotti, Erika Pellegrini, Francesca Molinaro, Grazia Lupi, Fiorenzo Pasini, Andrea Campostrini, Natascia Ion Popa, Florina Teofoli, Francesca Vincenzi, Monica Camilot, Marta Piacentini, Giorgio Bordugo, Andrea |
author_facet | Maguolo, Alice Rodella, Giulia Dianin, Alice Monge, Irene Messina, Martina Rigotti, Erika Pellegrini, Francesca Molinaro, Grazia Lupi, Fiorenzo Pasini, Andrea Campostrini, Natascia Ion Popa, Florina Teofoli, Francesca Vincenzi, Monica Camilot, Marta Piacentini, Giorgio Bordugo, Andrea |
author_sort | Maguolo, Alice |
collection | PubMed |
description | Introduction: Biotinidase deficiency (BD) is an autosomal recessive disease causing a defect in the biotin-releasing enzyme. Newborn screening (NBS) allows early diagnosis and treatment, ensuring excellent prognosis. The aim of this study was to describe our experience in the diagnosis, treatment, and follow-up showing key strategies and unsolved questions of the management of BD patients. Methods: We analyzed data of patients identified by the Regional Centre for Newborn Screening of Verona and followed by the Inherited Metabolic Disease Unit of Verona and Neonatal Intensive Care Unit of Bolzano, Italy, from 2014 to 2020. Results: Thirty-seven patients were diagnosed by NBS (five profound and 32 partial BD), with a total incidence of 1:5,996. All were started on biotin at diagnosis and presented no symptoms at follow-up. Analysis of parents and siblings led to identification of five asymptomatic patients with partial BD: one asymptomatic parent and four young siblings. Genetic analysis of the BTD gene identified 17 different genotypes and one mutation not previously known. Discussion: Our data confirm that NBS introduction had a dramatic impact on BD diagnosis, and the incidence has increased significantly compared to other areas. Partial defects are more common than profound and have a distinctive genotype. Partial BD treatment is still controversial even at what dose of biotin and for how long. At the end, BD treatment is very easy and inexpensive and prevents severe neurological damage. Sharing experiences is essential to achieving guidelines for treatment and follow-up and a better genotype–phenotype correlation. |
format | Online Article Text |
id | pubmed-8200396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82003962021-06-15 Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy Maguolo, Alice Rodella, Giulia Dianin, Alice Monge, Irene Messina, Martina Rigotti, Erika Pellegrini, Francesca Molinaro, Grazia Lupi, Fiorenzo Pasini, Andrea Campostrini, Natascia Ion Popa, Florina Teofoli, Francesca Vincenzi, Monica Camilot, Marta Piacentini, Giorgio Bordugo, Andrea Front Pediatr Pediatrics Introduction: Biotinidase deficiency (BD) is an autosomal recessive disease causing a defect in the biotin-releasing enzyme. Newborn screening (NBS) allows early diagnosis and treatment, ensuring excellent prognosis. The aim of this study was to describe our experience in the diagnosis, treatment, and follow-up showing key strategies and unsolved questions of the management of BD patients. Methods: We analyzed data of patients identified by the Regional Centre for Newborn Screening of Verona and followed by the Inherited Metabolic Disease Unit of Verona and Neonatal Intensive Care Unit of Bolzano, Italy, from 2014 to 2020. Results: Thirty-seven patients were diagnosed by NBS (five profound and 32 partial BD), with a total incidence of 1:5,996. All were started on biotin at diagnosis and presented no symptoms at follow-up. Analysis of parents and siblings led to identification of five asymptomatic patients with partial BD: one asymptomatic parent and four young siblings. Genetic analysis of the BTD gene identified 17 different genotypes and one mutation not previously known. Discussion: Our data confirm that NBS introduction had a dramatic impact on BD diagnosis, and the incidence has increased significantly compared to other areas. Partial defects are more common than profound and have a distinctive genotype. Partial BD treatment is still controversial even at what dose of biotin and for how long. At the end, BD treatment is very easy and inexpensive and prevents severe neurological damage. Sharing experiences is essential to achieving guidelines for treatment and follow-up and a better genotype–phenotype correlation. Frontiers Media S.A. 2021-05-31 /pmc/articles/PMC8200396/ /pubmed/34136440 http://dx.doi.org/10.3389/fped.2021.661416 Text en Copyright © 2021 Maguolo, Rodella, Dianin, Monge, Messina, Rigotti, Pellegrini, Molinaro, Lupi, Pasini, Campostrini, Ion Popa, Teofoli, Vincenzi, Camilot, Piacentini and Bordugo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Maguolo, Alice Rodella, Giulia Dianin, Alice Monge, Irene Messina, Martina Rigotti, Erika Pellegrini, Francesca Molinaro, Grazia Lupi, Fiorenzo Pasini, Andrea Campostrini, Natascia Ion Popa, Florina Teofoli, Francesca Vincenzi, Monica Camilot, Marta Piacentini, Giorgio Bordugo, Andrea Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy |
title | Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy |
title_full | Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy |
title_fullStr | Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy |
title_full_unstemmed | Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy |
title_short | Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy |
title_sort | newborn screening for biotinidase deficiency. the experience of a regional center in italy |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200396/ https://www.ncbi.nlm.nih.gov/pubmed/34136440 http://dx.doi.org/10.3389/fped.2021.661416 |
work_keys_str_mv | AT maguoloalice newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT rodellagiulia newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT dianinalice newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT mongeirene newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT messinamartina newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT rigottierika newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT pellegrinifrancesca newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT molinarograzia newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT lupifiorenzo newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT pasiniandrea newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT campostrininatascia newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT ionpopaflorina newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT teofolifrancesca newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT vincenzimonica newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT camilotmarta newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT piacentinigiorgio newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly AT bordugoandrea newbornscreeningforbiotinidasedeficiencytheexperienceofaregionalcenterinitaly |